FIRMAGON treatment involves an initial single dose followed by ongoing maintenance doses administered every 28 days for a duration determined by your doctor.
Understanding the typical course of FIRMAGON (degarelix) treatment involves two distinct phases: an initial loading dose and subsequent maintenance doses. This medication is typically used for advanced prostate cancer, and its duration is highly individualized based on the patient's response and the doctor's assessment.
Initial Treatment Phase
When you begin FIRMAGON therapy, you will receive a single, higher dosage only once. This initial dose is designed to quickly achieve therapeutic levels and lower relevant hormone levels.
Ongoing Maintenance Phase
Approximately 28 days after your initial dose, your doctor will administer your first maintenance dose of FIRMAGON. This maintenance dose is typically 80 mg, given as a single injection.
- Frequency: You will continue to receive this maintenance dose once every 28 days.
- Duration: The treatment continues for as long as your doctor deems it necessary and beneficial for your condition. This means there isn't a fixed end date, as the therapy is designed to manage the disease long-term under medical supervision. Your doctor will regularly assess your progress and determine the appropriate duration of your ongoing treatment.
FIRMAGON Dosing Schedule Overview
To summarize the typical administration schedule for FIRMAGON:
| Treatment Phase | Dosage | Frequency | Duration |
|---|---|---|---|
| Initial Dose | Higher (once) | Once | Single administration |
| Maintenance Dose | 80 mg | Once every 28 days | As long as your doctor recommends |
It is crucial to adhere strictly to your prescribed dosing schedule and attend all appointments for injections to ensure the medication's effectiveness in managing your condition. Always consult with your healthcare provider for personalized guidance regarding your specific treatment plan and its duration. For more general information on medications like FIRMAGON, reliable sources such as the National Cancer Institute or other reputable health organizations can be consulted.
